Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro

Clementi et al., Front. Microbiol., 10 July 2020, doi:10.3389/fmicb.2020.01704 (date from preprint)
Mar 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19hcq.org
In Vitro study showing greater inhibition for combined pre and post-exposure treatment for Vero E6 and Caco-2 cells.
Clementi et al., 31 Mar 2020, peer-reviewed, 10 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperHCQAll
Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro
Nicola Clementi, Elena Criscuolo, Roberta Antonia Diotti, Roberto Ferrarese, Matteo Castelli, Lorenzo Dagna, Roberto Burioni, Massimo Clementi, Nicasio Mancini
Frontiers in Microbiology, doi:10.3389/fmicb.2020.01704
While the SARS-CoV-2 pandemic is heavily hitting the world, it is of extreme importance that significant in vitro observations guide the quick set up of clinical trials. In this study, we evidence that the anti-SARS-CoV2 activity of a clinically achievable hydroxychloroquine concentration is maximized only when administered before and after the infection of Vero E6 and Caco-2 cells. This suggests that only a combined prophylactic and therapeutic use of hydroxychloroquine may be effective in limiting viral replication in patients.
ETHICS STATEMENT The study involving human participants was reviewed and approved by Ospedale San Raffaele IRB in the COVID-19 Biobanking project. The patient from whose samples the virus was isolated provided written informed consent. AUTHOR'S NOTE This manuscript has been released as a pre-print at bioRxiv preprint. doi: 10.1101/2020.03.29.014407, Hu et al. (2020) . AUTHOR CONTRIBUTIONS NC and NM conceived the study. EC, RD, and RF performed the experiments. NC, NM, EC, MCa, and MCl analyzed the data. NC, NM, EC, and RD wrote the manuscript. NC, NM, LD, RB, and MCl revised the manuscript. All authors contributed to the article and approved the submitted version. coronavirus (2019-nCoV) in vitro. Cell Res. 30, 1-3. doi: 10.1038/s41422-020-0282-0 Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., et al. (2020) . In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. doi: 10.1093/cid/ciaa237. [Epub ahead of print]. Zhou, D., Dai, S.-M., and Tong, Q. (2020). COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J. Antimicrob. Chemother. 63, 457-454. doi: 10.1093/jac/ dkaa114 Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest...
References
Chatre, Roubille, Vernhet, Jorgensen, Pers, Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature, Drug Saf, doi:10.1007/s40264-018-0689-4
Colson, Rolain, Lagier, Brouqui, Raoult, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, Int. J. Antimicrob. Agents, doi:10.1016/j.ijantimicag.2020.105932
Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect Dis, doi:10.1016/S1473-3099(20)30120-1
Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci. Trends, doi:10.5582/bst.2020.01047
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents, doi:10.1016/j.ijantimicag.2020.105949
Hirotsu, Mochizuki, Omata, Double-quencher probes improved the detection sensitivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by one-step RT-PCR, medRxiv, doi:10.1101/2020.03.17.20037903
Hu, Frieman, Insights from nanomedicine into chloroquine efficacy against COVID-19, Nat. Nanotechnol, doi:10.1038/s41565-020-0674-9
Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov, doi:10.1038/s41421-020-0156-0
Mehra, Desai, Kuy, Henry, Patel, Retraction: cardiovascular disease, drug therapy, and mortality in Covid-19, N. Engl. J. Med, doi:10.1056/NEJMc2021225
Mehra, Desai, Ruschitzka, Patel, RETRACTED: hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet, doi:10.1016/S0140-6736(20)31180-6
Science, The pandemic's first major research scandal erupts, Science, doi:10.1126/science.368.6495.1041
Tu, Chien, Yarmishyn, Lin, Luo et al., A review of SARS-CoV-2 and the ongoing clinical trials, IJMS, doi:10.3390/ijms21072657
Vincent, Bergeron, Benjannet, Erickson, Rollin et al., Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol. J, doi:10.1186/1743-422X-2-69
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel
{ 'DOI': '10.3389/fmicb.2020.01704', 'ISSN': ['1664-302X'], 'URL': 'http://dx.doi.org/10.3389/fmicb.2020.01704', 'alternative-id': ['10.3389/fmicb.2020.01704'], 'author': [ {'affiliation': [], 'family': 'Clementi', 'given': 'Nicola', 'sequence': 'first'}, {'affiliation': [], 'family': 'Criscuolo', 'given': 'Elena', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Diotti', 'given': 'Roberta Antonia', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Ferrarese', 'given': 'Roberto', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Castelli', 'given': 'Matteo', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Dagna', 'given': 'Lorenzo', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Burioni', 'given': 'Roberto', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Clementi', 'given': 'Massimo', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Mancini', 'given': 'Nicasio', 'sequence': 'additional'}], 'container-title': 'Frontiers in Microbiology', 'container-title-short': 'Front. Microbiol.', 'content-domain': {'crossmark-restriction': True, 'domain': ['frontiersin.org']}, 'created': {'date-parts': [[2020, 7, 10]], 'date-time': '2020-07-10T05:16:55Z', 'timestamp': 1594358215000}, 'deposited': { 'date-parts': [[2020, 7, 10]], 'date-time': '2020-07-10T05:16:56Z', 'timestamp': 1594358216000}, 'indexed': {'date-parts': [[2024, 5, 14]], 'date-time': '2024-05-14T18:33:52Z', 'timestamp': 1715711632477}, 'is-referenced-by-count': 15, 'issued': {'date-parts': [[2020, 7, 10]]}, 'license': [ { 'URL': 'https://creativecommons.org/licenses/by/4.0/', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2020, 7, 10]], 'date-time': '2020-07-10T00:00:00Z', 'timestamp': 1594339200000}}], 'link': [ { 'URL': 'https://www.frontiersin.org/article/10.3389/fmicb.2020.01704/full', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '1965', 'original-title': [], 'prefix': '10.3389', 'published': {'date-parts': [[2020, 7, 10]]}, 'published-online': {'date-parts': [[2020, 7, 10]]}, 'publisher': 'Frontiers Media SA', 'reference': [ { 'DOI': '10.1007/s40264-018-0689-4', 'article-title': 'Cardiac complications attributed to chloroquine and hydroxychloroquine: ' 'a systematic review of the literature', 'author': 'Chatre', 'doi-asserted-by': 'publisher', 'first-page': '919', 'journal-title': 'Drug Saf.', 'key': 'B1', 'volume': '41', 'year': '2018'}, { 'DOI': '10.1016/j.ijantimicag.2020.105932', 'article-title': 'Chloroquine and hydroxychloroquine as available weapons to fight ' 'COVID-19', 'author': 'Colson', 'doi-asserted-by': 'publisher', 'first-page': '105932', 'journal-title': 'Int. J. Antimicrob. Agents', 'key': 'B2', 'volume': '55', 'year': '2020'}, { 'DOI': '10.1016/S1473-3099(20)30120-1', 'article-title': 'An interactive web-based dashboard to track COVID-19 in real time', 'author': 'Dong', 'doi-asserted-by': 'publisher', 'first-page': '533', 'journal-title': 'Lancet Infect Dis', 'key': 'B3', 'volume': '20', 'year': '2020'}, { 'DOI': '10.5582/bst.2020.01047', 'article-title': 'Breakthrough: chloroquine phosphate has shown apparent efficacy in ' 'treatment of COVID-19 associated pneumonia in clinical studies', 'author': 'Gao', 'doi-asserted-by': 'publisher', 'first-page': '72', 'journal-title': 'Biosci. Trends', 'key': 'B4', 'volume': '14', 'year': '2020'}, { 'DOI': '10.1016/j.ijantimicag.2020.105949', 'article-title': 'Hydroxychloroquine and azithromycin as a treatment of COVID-19: results ' 'of an open-label non-randomized clinical trial', 'author': 'Gautret', 'doi-asserted-by': 'publisher', 'journal-title': 'Int. J. Antimicrob. Agents', 'key': 'B5', 'year': '2020'}, { 'DOI': '10.1101/2020.03.17.20037903', 'article-title': 'Double-quencher probes improved the detection sensitivity of severe ' 'acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by one-step ' 'RT-PCR', 'author': 'Hirotsu', 'doi-asserted-by': 'publisher', 'journal-title': 'medRxiv', 'key': 'B6', 'year': '2020'}, { 'DOI': '10.1038/s41565-020-0674-9', 'article-title': 'Insights from nanomedicine into chloroquine efficacy against COVID-19', 'author': 'Hu', 'doi-asserted-by': 'publisher', 'first-page': '247', 'journal-title': 'Nat. Nanotechnol', 'key': 'B7', 'volume': '15', 'year': '2020'}, { 'DOI': '10.1038/s41421-020-0156-0', 'article-title': 'Hydroxychloroquine, a less toxic derivative of chloroquine, is ' 'effective in inhibiting SARS-CoV-2 infection in vitro', 'author': 'Liu', 'doi-asserted-by': 'publisher', 'first-page': '16', 'journal-title': 'Cell Discov', 'key': 'B8', 'volume': '6', 'year': '2020'}, { 'DOI': '10.1056/NEJMc2021225', 'article-title': 'Retraction: cardiovascular disease, drug therapy, and mortality in ' 'Covid-19', 'author': 'Mehra', 'doi-asserted-by': 'publisher', 'first-page': '2582', 'journal-title': 'N. Engl. J. Med', 'key': 'B9', 'volume': '382', 'year': ''}, { 'DOI': '10.1016/S0140-6736(20)31180-6', 'article-title': 'RETRACTED: hydroxychloroquine or chloroquine with or without a ' 'macrolide for treatment of COVID-19: a multinational registry analysis', 'author': 'Mehra', 'doi-asserted-by': 'publisher', 'first-page': '1820', 'journal-title': 'Lancet', 'key': 'B10', 'volume': '395', 'year': ''}, { 'DOI': '10.1126/science.368.6495.1041', 'article-title': "The pandemic's first major research scandal erupts", 'doi-asserted-by': 'publisher', 'first-page': '1', 'journal-title': 'Science', 'key': 'B11', 'volume': '386', 'year': '2020'}, { 'DOI': '10.3390/ijms21072657', 'article-title': 'A review of SARS-CoV-2 and the ongoing clinical trials', 'author': 'Tu', 'doi-asserted-by': 'publisher', 'first-page': '2657', 'journal-title': 'IJMS', 'key': 'B12', 'volume': '21', 'year': '2020'}, { 'DOI': '10.1186/1743-422X-2-69', 'article-title': 'Chloroquine is a potent inhibitor of SARS coronavirus infection and ' 'spread', 'author': 'Vincent', 'doi-asserted-by': 'publisher', 'first-page': '69', 'journal-title': 'Virol. J.', 'key': 'B13', 'volume': '2', 'year': '2005'}, { 'DOI': '10.1038/s41422-020-0282-0', 'article-title': 'Remdesivir and chloroquine effectively inhibit the recently emerged ' 'novel coronavirus (2019-nCoV) in vitro', 'author': 'Wang', 'doi-asserted-by': 'publisher', 'first-page': '1', 'journal-title': 'Cell Res', 'key': 'B14', 'volume': '30', 'year': '2020'}, { 'DOI': '10.1093/cid/ciaa237', 'article-title': 'In vitro antiviral activity and projection of optimized dosing design ' 'of hydroxychloroquine for the treatment of severe acute respiratory ' 'syndrome coronavirus 2 (SARS-CoV-2)', 'author': 'Yao', 'doi-asserted-by': 'publisher', 'journal-title': 'Clin. Infect. Dis', 'key': 'B15', 'year': '2020'}, { 'DOI': '10.1093/jac/dkaa114', 'article-title': 'COVID-19: a recommendation to examine the effect of hydroxychloroquine ' 'in preventing infection and progression', 'author': 'Zhou', 'doi-asserted-by': 'publisher', 'first-page': '457', 'journal-title': 'J. Antimicrob. Chemother.', 'key': 'B16', 'volume': '63', 'year': '2020'}], 'reference-count': 16, 'references-count': 16, 'relation': { 'has-preprint': [ { 'asserted-by': 'object', 'id': '10.1101/2020.03.29.014407', 'id-type': 'doi'}]}, 'resource': {'primary': {'URL': 'https://www.frontiersin.org/article/10.3389/fmicb.2020.01704/full'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': [], 'subtitle': [], 'title': 'Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects ' 'in vitro', 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.3389/crossmark-policy', 'volume': '11'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit